Ingevity Corporation
NYSE:NGVTChemicals - Specialty
+$0.81 today
- Market cap
- $1.97B
- Beta
- 1.19
- P/E (TTM)
- -20.0
- EPS (TTM)
- -$3.62
Volume 0.37M
Average 0.26M
NGVT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Ingevity CorporationNYSE: NGVT
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA declines year over year
Q3 FY2026 EBITDA of $51.1M fell 52.9% year over year, behind the -4.9% change in trailing-twelve-month EBITDA. Sequentially, it fell 33.9% from the prior quarter. Over 3 fiscal years it compounded at -56.0% a year.
Context
- EBITDA amounted to 3.2% of revenue in FY2025, down 20.2 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of $442.88M (+1084.2%) for the fiscal year ending Dec 2026, a step up from the +111.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $51.1M-33.9% QoQ
- Last fiscal yearDec 2025
- $37.4M+111.4% YoY
- LTMSep 2026
- $136.5M-4.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -52.9% | +223.8% | +276.7 pp |
| 1 year | +111.4% | +1084.2% | +972.8 pp |
| 3-year CAGR | -56.0% | +137.6% | +193.7 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 37.4M USD
- Year-over-year change
- +111.4%
- 4-year CAGR
- -41.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 37.4M | +111.4% |
| FY2024 | 2024-12-31 | (329.5M) | -260.0% |
| FY2023 | 2023-12-31 | 206M | -53.2% |
| FY2022 | 2022-12-31 | 440.2M | +35.7% |
| FY2021 | 2021-12-31 | 324.4M | — |
EBITDA vs competitors
How NGVT compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -4.9% is the 6th highest of 11, against a peer median of +17.1%.
- EBITDA amounts to 12.1% of revenue for NGVT, versus a peer median of 11.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AAUCAllied Gold Corporation | LTM Jun 2026 | $444.19M USD | +545.7% | +27.3% | 29.8% |
| LTM Jun 2026 | $380M USD | +176.5% | — | 20.6% | |
| LTM Apr 2026 | $368.4M USD | +142.5% | -20.3% | 17.3% | |
| LTM Sep 2026 | $232.84M USD | +46.9% | +6.3% | 11.5% | |
| LTM Jun 2026 | $181M USD | -12.7% | -7.0% | 9.8% | |
| LTM Sep 2026 | $136.5M USD | -4.9% | -56.0% | 12.1% | |
| LTM Jun 2026 | $74.6M USD | -89.6% | -36.4% | 1.1% | |
ELVRElevra Lithium Limited | FY2025 | -A$38.8M AUD | +88.6% | — | 18.7% |
| LTM Jun 2026 | -$166M USD | -151.6% | -34.7% | 2.9% | |
| LTM Mar 2026 | -$222.5M USD | -130.9% | — | 6.5% | |
| LTM Sep 2026 | -CA$245.01M CAD | -134.8% | — | — | |
| Peer median (excluding NGVT) | — | +17.1% | -13.6% | 11.5% | |
Competitors are the stored peer set for NGVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.39B | 1.67B | 1.69B | 1.41B | 1.17B |
| Cost of Revenue | 878.7M | 1.1B | 1.22B | 951.7M | 706.1M |
| Gross Profit | 512.8M | 570.1M | 471.9M | 454.7M | 461.5M |
| Gross Margin | 36.9% | 34.2% | 27.9% | 32.3% | 39.5% |
| Research & Development | 26.3M | 30.3M | 31.8M | 28.1M | 28.4M |
| Selling, General & Admin | 179.3M | 198.8M | 183.7M | 166.7M | 171.2M |
| Operating Expenses | 205.6M | 229.1M | 215.5M | 194.8M | 199.6M |
| Depreciation & Amortization | 109.9M | 108.8M | 122.8M | 108.3M | 106.4M |
| EBITDA | 324.4M | 440.2M | 206M | (329.5M) | 37.4M |
| EBITDA Margin | 23.3% | 26.4% | 12.2% | -23.4% | 3.2% |
| Operating Income | 307.2M | 341M | 256.4M | 259.9M | 261.9M |
| Operating Margin | 22.1% | 20.4% | 15.2% | 18.5% | 22.4% |
| Interest Income | 4M | 5.8M | 6.3M | 6.9M | 4.4M |
| Interest Expense | 51.7M | 61.8M | 93.3M | 97.8M | 77.1M |
| Other Income / Expenses | (144.4M) | (71.4M) | (266.5M) | (795.5M) | (404M) |
| Income Before Tax | 162.8M | 269.6M | (10.1M) | (535.6M) | (142.1M) |
| Pre-Tax Margin | 11.7% | 16.2% | -0.6% | -38.1% | -12.2% |
| Income Tax Expense | 44.7M | 58M | (4.7M) | (105.3M) | 8.2M |
| Net Income | 118.1M | 211.6M | (5.4M) | (430.3M) | (167.1M) |
| Net Margin | 8.5% | 12.7% | -0.3% | -30.6% | -14.3% |
| EPS (Basic) | 2.97 | 5.50 | (0.15) | (11.85) | (4.61) |
| EPS (Diluted) | 2.95 | 5.50 | (0.15) | (11.85) | (4.61) |
| Weighted Avg Shares | 39.8M | 38.47M | 36.5M | 36.32M | 36.2M |
| Weighted Avg Shares (Diluted) | 40.06M | 38.47M | 36.5M | 36.32M | 36.2M |
Ingevity Corporation
NYSE:NGVT
Intrinsic Alpha fair value
Locked
Current Price
$58.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.